There were many reports confirming that HRAS could activate ERK signalling pathways 36-39, and we verified that p-ERK was upregulated when HRAS was overexpressed in RCC cells (Figure 6F), while p-ERK was downregulated when HRAS was inhibited in RCC cells (Figure 6G). This evidence concerns the gene HRAS and renal cell carcinoma.